Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Retained Earnings (2020 - 2025)

Mirum Pharmaceuticals has reported Retained Earnings over the past 6 years, most recently at -$667.5 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$667.5 million for Q4 2025, down 3.62% from a year ago — trailing twelve months through Dec 2025 was -$667.5 million (down 3.62% YoY), and the annual figure for FY2025 was -$667.5 million, down 3.62%.
  • Retained Earnings for Q4 2025 was -$667.5 million at Mirum Pharmaceuticals, down from -$661.8 million in the prior quarter.
  • Over the last five years, Retained Earnings for MIRM hit a ceiling of $920000.0 in Q3 2024 and a floor of -$667.5 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$317.7 million (2021), compared with a mean of -$304.5 million.
  • Biggest five-year swings in Retained Earnings: tumbled 2466723.08% in 2022 and later soared 203.82% in 2023.
  • Mirum Pharmaceuticals' Retained Earnings stood at -$35000.0 in 2021, then plummeted by 520.0% to -$217000.0 in 2022, then plummeted by 256231.34% to -$556.2 million in 2023, then decreased by 15.81% to -$644.2 million in 2024, then dropped by 3.62% to -$667.5 million in 2025.
  • The last three reported values for Retained Earnings were -$667.5 million (Q4 2025), -$661.8 million (Q3 2025), and $352000.0 (Q2 2025) per Business Quant data.